Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Treatment of early stage rheumatoid arthritis should continue to include conventional synthetic disease modifying drugs (DMARDs) plus steroids, advises the European League against Rheumatism (EULAR) in its latest recommendations on managing the disease, published in the Annals of the Rheumatic Diseases.
But the steroid dose should not exceed 10 mg a day, and should only be prescribed for a maximum of six months, says EULAR.
Only if this strategy fails to significantly ease or reverse symptoms, should a biological DMARD be deployed, it says. And only then, if the disease is likely to progress or is severe. Otherwise, another conventional synthetic DMARD should be used, along with steroids.
The latest recommendations on the safety and effectiveness of DMARDs to treat rheumatoid arthritis update those published in 2010 in the wake of the availability of new drugs and further experience with treatment strategies.
They publish just ahead of the start of the international annual American College of Rheumatology (ACR) congress, which runs from October 25-30 in San Diego.
DMARDs, which are the mainstay of treatment for the disease, work by blocking the inflammatory processes characteristic of rheumatoid arthritis and curbing the amount of associated joint damage. They are either synthetic or biological.
The 2013 recommendations were developed by an international taskforce, which included four patient representatives, 24 rheumatologists, an infectious disease specialist, a health economist and three research fellows from 11 European countries and the US.
The taskforce drew on published evidence from three systematic reviews on the use of synthetic and biological DMARDs for rheumatoid arthritis, and expert opinion, to reach a consensus on 14 treatment recommendations and three guiding principles.
The recommendations emphasise that not only should treatment be based on shared decision making between rheumatologist and patient, but that rheumatologists should primarily manage patients with this condition.
And treatment should take into consideration the high personal, societal, and medical costs of rheumatoid arthritis.
Other key clinical recommendations include:
The rapidly evolving treatment of rheumatoid arthritis is likely to prompt the need for further updates in two to three years' time, say the taskforce authors.
"Until then, we hope that the current recommendations find their way into clinical practice either directly or through national societies that may wish to use them as a framework for development of local guidance documents," they suggest.
Author: Josef S Smolen, Robert Landewé, Ferdinand C Breedveld, Maya Buch, Gerd Burmester, Maxime Dougados, Paul Emery, Cécile Gaujoux-Viala, Laure Gossec, Jackie Nam, Soﬁa Ramiro, Kevin Winthrop, Maarten de Wit, Daniel Aletaha, Neil Betteridge, Johannes W J Bijlsma, Maarten Boers, Frank Buttgereit, Bernard Combe, Maurizio Cutolo, Nemanja Damjanov, Johanna M W Hazes, Marios Kouloumas, Tore K Kvien, Xavier Mariette, Karel Pavelka, Piet L C M van Riel, Andrea Rubbert-Roth, Marieke Scholte-Voshaar, David L Scott, Tuulikki Sokka-Isler, John B Wong, Désirée van der Heijde
Ann Rheum Dis: doi:10.1136/annrheumdis-2013-204573
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Arthritis / Rheumatology category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
BMJ. "Don't use biological disease modifying drugs in rheumatoid arthritis, to begin with, doctors urged." Medical News Today. MediLexicon, Intl., 25 Oct. 2013. Web.
10 Dec. 2013. <http://www.medicalnewstoday.com/releases/267881>
BMJ. (2013, October 25). "Don't use biological disease modifying drugs in rheumatoid arthritis, to begin with, doctors urged." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/267881.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.